Table 4 Demographic and clinical characteristics of patients across the GVHD groups.

From: Application of latent class analysis in diagnosis of graft-versus-host disease by serum markers after allogeneic haematopoietic stem cell transplantation

Characteristics

GVHD (n = 43)

Non- GVHD (n = 51)

P value

LDH (U/L), mean (SD)

2.68 (0.11)

2.62 (0.14)

0.028*

UA (mg/dl), mean (SD)

3.91 (0.87)

3.76 (0.87)

0.401*

Cr (mg/dL), mean (SD)

0.95 (0.16)

0.88 (0.13)

0.020*

Age (years), mean (SD)

35.20 (9.86)

34.82 (11.19)

0.866*

Donor age (years), mean (SD)

35.32 (12.53)

31.77 (9.04)

0.177*

BMI (kg/m2), mean (SD)

25.22 (4.0)

25.31 (4.65)

0.927*

Gender, n (%)

  

0.459**

Male

18 (52.9)

27 (45.0)

 

Female

16 (47.1)

33 (55.0)

 

Smoking, n (%)

  

0.377**

Never

29 (85.3)

52 (88.1)

 

Past

5 (14.7)

5 (8.5)

 

Current

0 (0)

2 (3.4)

 

GVHD Prophylaxis, n (%)

  

0.214**

CSA+MTX

27 (79.4)

54 (90.0)

 

CSA+MTX+ATG

7 (20.6)

6 (10.0)

 

Conditioning regimen, n (%)

  

0.515**

Bu-Cy

19 (55.9)

34 (56.7)

 

Bu-Fu

9 (26.5)

20 (33.3)

 

Bu-Fu-ATG

6 (17.6)

6 (10.0)

 

Blood Group, n (%)

  

0.280**

A

11 (32.4)

15 (25.9)

 

B

11 (32.4)

11 (19.0)

 

AB

5 (8.7)

10 (17.2)

 

O

9 (26.5)

22 (37.9)

 

DP-Gender, n (%)

  

0.256**

M-M

5 (14.7)

14 (23.3)

 

M-F

13 (38.2)

19 (31.7)

 

F-F

3 (8.8)

12 (20.0)

 

F-M

13 (38.2)

15 (25.0)

 
  1. The groups of GVHD (with and without) were based on the optimal composite test (i.e., combination of Cr, LDH, and UA adjusting for age, DP-gender, GVHD prophylaxis, and conditioning regimen). GVHD: graft-versus-host disease; SD: standard deviation; LDH: lactate dehydrogenase; UA: uric acid; Cr: creatinine; BMI: body mass index; CSA: cyclosporine A; MTX: Methotrexate; ATG: anti-thymocyte globulin; Bu: busulfan; Cy: cyclophosphamide; Fu: fludarabine; M: male; F: female; * T-test; **χ2.
Back to article page